Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic
British Journal of Anaesthesia · 2026
DOI: 10.1016/j.bja.2025.11.028 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Anaesthesia, 2026. Verfasst von Liqun Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China. Hauptthemen laut MEDLINE: Anesthetics, Local, Bupivacaine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: LL10 is a novel long-acting local anaesthetic composed of QX-OH 1.26% and levobupivacaine hydrochloride 0.325%. This first-in-human trial assessed the safety, tolerability, efficacy, and pharmacokinetic profile of LL10. METHODS: We investigated three administration routes: s.c. infiltration, femoral nerve block (FNB), and transversus abdominis plane block (TAPB), with levobupivacaine as a positive control (n=18 total, six per route). For s.c. infiltration, 40 subjects received concentration escalation of LL10 (4 ml, seven cohorts); for FNB, 30 received LL10 at escalating concentrations (20 ml, six cohorts); and for TAPB, 49 received 1.26%/0.325% LL10 at escalating volumes (25-55 ml, seven cohorts). Each LL10 cohort included a placebo control (n=20). Safety evaluations included vital signs, adverse events (AEs), physical examinations, and laboratory tests. Sensory block was evaluated using pinprick, mechanical pain thresholds, and transcutaneous electrical stimulation. Motor block was evaluated via lower limb muscle strength grading. Plasma pharmacokinetics of QX-OH and levobupivacaine were investigated. RESULTS: None of the 137 enrolled subjects developed severe AEs. Dose-dependent systemic AEs including dizziness, perioral and tongue numbness, and cardiovascular symptoms were observed after TAPB; all resolved spontaneously. LL10 showed linear pharmacokinetics. The 1.26%/0.325% LL10 demonstrated prolonged FNB duration compared with levobupivacaine 0.325% (median, 25.0 [21.8-29.5] h vs 15.5 [6.0-21.2] h; P = 0.021). CONCLUSIONS: The 1.26%/0.325% LL10 was tolerated in healthy volunteers at doses up to 40 ml (equivalent to 7/1.81 mg kg-1). LL10 produced prolonged local anaesthesia in FNB compared with levobupivacaine 0.325%, but not in s.c. infiltration or transversus abdominus plane block. CLINICAL TRIAL REGISTRATION: ChiCTR2200064437 (Chinese Clinical Trial Registry).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
- Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China; Laboratory of Anaesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational…
- Shandong New Time Pharmaceutical Co., Ltd, Linyi, Shandong, PR China.
Zitieren
APA
Fang, L., Liu, J., Xu, M., Zhong, J., He, Y., Zhang, J., Liu, J., & Zhang, W. (2026). Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.11.028
Vancouver
Fang L, Liu J, Xu M, Zhong J, He Y, Zhang J, et al. Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic. British Journal of Anaesthesia. 2026. doi:10.1016/j.bja.2025.11.028
BibTeX
@article{Fang2026,
author = {Fang, Liqun and Liu, Jing and Xu, Mingzhe and Zhong, Jie and He, Yi and Zhang, Jianxiang and Liu, Jin and Zhang, Wensheng},
title = {Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic},
journal = {British Journal of Anaesthesia},
year = {2026},
doi = {10.1016/j.bja.2025.11.028}
}
EUVIMED